No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 2, 2000, Pages 151-159

  Laine, Kari ^a,b   Tybring, Gunnel ^a,b   Bertilsson, Leif ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; MEPHENYTOIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGED; ALLELISM; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; SEX CHARACTERISTICS; SWEDEN;

EID: 0033837621     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.108949     Document Type: Article

References (37)

1. Genetic polymorphism of S-mephenytoin hydroxylation
2. Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders
3. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
4. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
5. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
6. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
7. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
8. Pharmacokinetics and metabolism of omeprazole in man
9. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators
10. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
11. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
12. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
13. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
14. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
15. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study
16. Inhibition and induction of human cytochrome P450 (CYP) enzymes
17. Oral contraceptive steroids impair the elimination of theophylline
18. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination
19. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics
20. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics
21. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans?
22. Metabolism of 17 alpha-ethynylestradiol in humans
23. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
24. Oral contraceptives: Are drug interactions of clinical significance?
25. Dose linearity study of selegiline pharmacokinetics after oral administration: Evidence for strong drug interaction with female sex steroids
26. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences
27. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio
28. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
29. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography
30. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19
31. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
32. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
33. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
34. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
35. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women
36. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population